| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/05/2005 | US20050096381 Derivatives of isoflavones |
| 05/05/2005 | US20050096380 For therapy of diabetes |
| 05/05/2005 | US20050096378 Fundic relaxation; dyspepsia, early satiety, bloating and anorexia; 1-[3-[[(3,4-dihydro-2H-1-benzopyran-2-yl- )methyl]amino]-2-hydroxypropyl]-2,4-imidazolidinedione |
| 05/05/2005 | US20050096375 through augmentation of glutamatergic neurotransmission; Central nervous system disorders, cognitive disorders, schizophrenia, dementia; 3-aza-bicyclo[3.1.0]hexanes; Thiophene-2-carboxylic acid (3-cyclohexylmethyl-3-aza-bicyclo[3.1.0]hex-6-ylmethyl)-(3-fluoro-4-morpholin-4-yl-phenyl)-amide |
| 05/05/2005 | US20050096372 Wound healing agents; antiproliferative agents; antiinflammatory agents; skin disorders; anticancer agents; N'4,5-dimethyl-N'4-(5-nitro-2-pyridyl)-3-(2,6-dichlorophenyl)isoxazole-4-carbohydrazide |
| 05/05/2005 | US20050096371 Topical pharmaceutical compositions |
| 05/05/2005 | US20050096370 Blocking gene expression; antihypoxic agents |
| 05/05/2005 | US20050096369 Compositions and methods for treating cellular proliferation disorders |
| 05/05/2005 | US20050096368 Heterocyclo-substituted imidazoles for the treatment of inflammation |
| 05/05/2005 | US20050096367 preventing, improving and/or treating metabolic syndrome, fatty liver, NASH and liver disorders |
| 05/05/2005 | US20050096365 Pharmaceutical compositions with synchronized solubilizer release |
| 05/05/2005 | US20050096364 Iminothiazolidinones as inhibitors of HCV replication |
| 05/05/2005 | US20050096363 Activator of peroxisome proliferator-activated receptor delta |
| 05/05/2005 | US20050096362 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| 05/05/2005 | US20050096358 Treating rheumatoid arthritis, psoriasis, reperfusion injury, cardiovascular , autoimmune, inflammatory disorders and bronchial asthma |
| 05/05/2005 | US20050096357 Antibiotics; therapy for infections which is caused by drug-resistant Streptococcus, or bacteria infections |
| 05/05/2005 | US20050096356 2-[[6-Methoxy-3-pyridinyl]methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide hydrochloride salt or its tautomer; treating retinopathy or age-related macula degeneration |
| 05/05/2005 | US20050096354 Process for the preparation of substituted aryl pyrazoles |
| 05/05/2005 | US20050096351 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 05/05/2005 | US20050096350 Halo substituted benzo[b]thiophenes as therapeutic agents |
| 05/05/2005 | US20050096349 Methods to prevent or ameliorate medication-, procedure-or stress-induced cognitive and speech dysfunction and methods to optimize cognitive and speech functioning |
| 05/05/2005 | US20050096348 non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile |
| 05/05/2005 | US20050096347 Beta3-Adrenoreceptor agonists, agonist compositions and methods of using |
| 05/05/2005 | US20050096344 controlling signal transduction; anticancer agents; antitumor agents; angiogenesis inhibitors; atherosclerosis; vision defects; antidiabetic agents; antiinflammatory agents; antiischemic agents |
| 05/05/2005 | US20050096343 pharmocophores of quinolone and oxazolidinone chemicaly linked; against a variety of multi-drag resistant bacteria; staphylococci, enterococci, Moraxella catarrhalis, haemophilus influenza, bacteroides, Clostridia, Mycobacterium tuberculosis, Mycobacterium avium |
| 05/05/2005 | US20050096342 Neurodegenerative disorders |
| 05/05/2005 | US20050096341 Novel tiotropium salts, process for the preparation and pharmaceutical compositions thereof |
| 05/05/2005 | US20050096340 lipophilic derivatives of paclitaxel, camptothecin, docetaxel or derivatives thereof; tocopherol succinate paclitaxel for example; emulsions for drug delivery, treating cancer; increased plasma elimination half-life compared to the parent therapeutic drug |
| 05/05/2005 | US20050096335 Heteroaryl - fused nitrogen heterocycles as therapeutic agents |
| 05/05/2005 | US20050096334 Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome |
| 05/05/2005 | US20050096333 Quinazoline derivatives as medicaments |
| 05/05/2005 | US20050096332 Use of tyrosine kinase inhibitors for the treatment of inflammatory processes |
| 05/05/2005 | US20050096331 Alkyl carboxylic acids and their derivatives; antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds; better efficacy, potency and lower toxicity |
| 05/05/2005 | US20050096330 N-(indolecarbonyl) piperazine derivatives |
| 05/05/2005 | US20050096329 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants |
| 05/05/2005 | US20050096328 Certain 1-(D-cycloproplyglycinyl)-4-piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa |
| 05/05/2005 | US20050096326 4-(4-methylpiperazin-1-yl)4V-(4-morpholinophenyl)-indan-2-carboxamide; h5-HT1B receptor antagonist; serotonin-mediated disorders; oral bioavailability |
| 05/05/2005 | US20050096321 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates |
| 05/05/2005 | US20050096320 potent inhibitors of cyclic guanosine 3',5'-monophosphate-metabolizing phosphodiesterases (cGMP-PDEs)/phosphodiesterase isoenzymes PDE-I, PDE-II, PDE-V; therapeutic, antiaggregatory, antithrombotic, antiproliferative, antivasospastic, vasodilatory, natriuretic and diuretic effects; erectile dysfunction |
| 05/05/2005 | US20050096319 Identification of compounds that inhibit replication of human immunodeficiency virus |
| 05/05/2005 | US20050096318 (+)-(2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethyl-2-morpholinol; treating depression, attention deficit hyperactivity disorder (ADHD), obesity, migraine, sexual dysfunction, Parkinson's disease, Alzheimer's disease, or addiction to cocaine or nicotine |
| 05/05/2005 | US20050096316 Quinoline derivatives(2) |
| 05/05/2005 | US20050096315 Fluorinated resorufin compounds and their application |
| 05/05/2005 | US20050096314 Treatment of cancers with methylol-containing compounds and at least one electrolyte |
| 05/05/2005 | US20050096313 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic |
| 05/05/2005 | US20050096312 Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders |
| 05/05/2005 | US20050096311 comprising an anticonvulsant and a neuroactive modulator; eg childhood disorders, cognitive disorders, substance disorders, schizophrenia, psychotic disorders mood disorders, anxiety disorders, somatoform disorders, factitious disorders, dissociative disorders, sexual disorders, gender identity disorders |
| 05/05/2005 | US20050096310 Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine |
| 05/05/2005 | US20050096309 For use as anticoagulant agents for therapy of thromboembolic disorders |
| 05/05/2005 | US20050096308 Antibacterial agents |
| 05/05/2005 | US20050096307 for the treatment or prevention of a vascular condition, diabetes, obesity or lowering a concentration of a sterol in plasma of a mammal |
| 05/05/2005 | US20050096306 Such as 7-[-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(1-carboxy-1-methylethoxyimino)acetamido]-3-[3-amino-4-(3-aminopropyl)-2-methyl-1-pyrazolio]methyl-3-cephem-4-carboxylate; antimicrobial agents; synthesis |
| 05/05/2005 | US20050096305 Augmentation of antipsychotic agent pharmacotherapy with chromium picolinate supplementation |
| 05/05/2005 | US20050096304 Method of treating cancer using dithiocarbamate derivatives |
| 05/05/2005 | US20050096303 Cardiovascular protection using anti-aldosteronic progestins |
| 05/05/2005 | US20050096302 Administering steroids to treat artherosclerosis |
| 05/05/2005 | US20050096301 Low dose estrogen for treatment of osteoporosis |
| 05/05/2005 | US20050096300 A 19-nor-vitamin D analog; suppression of secondary hyperparathyroidism of renal osteodystrophy; high binding to vitamin D receptors, low intestinal calcium transport activity, as compared to 1 alpha ,25-dihydroxyvitamin D3; very low ability to mobilize calcium from bone; no calcemic activity |
| 05/05/2005 | US20050096299 Minimizing gastrointestinal side effects with bone resorption |
| 05/05/2005 | US20050096297 Antibacterial agents |
| 05/05/2005 | US20050096296 Solubility of drugs is enhanced with solubilizers for drugs such as pioglitazone, zafilukast, simvastatin, atarvastin or fenofifrate |
| 05/05/2005 | US20050096294 Novel anti-coagulant |
| 05/05/2005 | US20050096293 Analogs of nitrobenzylthioinosine |
| 05/05/2005 | US20050096287 Enhance delivery of oligonucleotides, nucleosides, nucleic acids by injection or applying on skin a solution in water |
| 05/05/2005 | US20050096281 Administering cognition activators to improve memory and treat cognitive decline or senility by administering extracts of plants |
| 05/05/2005 | US20050096279 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
| 05/05/2005 | US20050096274 Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
| 05/05/2005 | US20050096266 Administering trypsin inhibitor and amino acid |
| 05/05/2005 | US20050096258 Methods and compositions for treating gastrointestinal tract mucin production associated disease conditions |
| 05/05/2005 | US20050096257 Administering platelet derived growth factor antagonist and endothelial growth factor antagonist |
| 05/05/2005 | US20050096256 Compositions for manipulating the lifespan and stress response of cells and organisms |
| 05/05/2005 | US20050096253 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion |
| 05/05/2005 | US20050096229 Biocidal compounds and their preparation |
| 05/05/2005 | US20050095710 Antisense modulation of PTP1B expression |
| 05/05/2005 | US20050095686 Preparing starch composition to improve structure, texture and stability of food; for use in prevention and treatment of infection, immunological and tumor disorders |
| 05/05/2005 | US20050095681 Intracellular modulators of apoptopic cell death pathways |
| 05/05/2005 | US20050095663 Via 6-(4-chlorophenyl)-2-(2'-pentyn-4'-ene-1-yl)-3(2H)-pyridazinone for inhibition of delta-9 fatty acid desaturase |
| 05/05/2005 | US20050095306 Side effect reduction of bone marrow suppression (leukopenia) induced by anticancer chemotherapy and/or radiotherapy |
| 05/05/2005 | US20050095304 Composition and method for smoke detoxification |
| 05/05/2005 | US20050095300 Controlled release analgesic suspensions |
| 05/05/2005 | US20050095299 Administering non-steroidal antiinflammatory drugs such as ibuprofen, or acetaminophen via a liquid suspension; particle core with enteric and insoluble polymer coatings; immediate and sustained release dosages |
| 05/05/2005 | US20050095297 Nanoparticulate formulations of fenofibrate |
| 05/05/2005 | US20050095294 Modafinil modified release pharmaceutical compositions |
| 05/05/2005 | US20050095293 Bioavailability of drug independent of gastric pH; core comprised of water soluble acid(s) of tartaric acid, fumaric acid, succinic acid, citric acid, malic acid, glutamic acid, and/or aspartic acid or salts; acid resistance; drug delivery |
| 05/05/2005 | US20050095292 Sustained release pharmaceutical compositions |
| 05/05/2005 | US20050095291 Tamper-resistant oral opioid agonist formulations |
| 05/05/2005 | US20050095290 comprising pharmacologically active substance, drug absorbefacient and taurine compound or polyamine; suppressing or preventing damage of the intestinal mucous membrane |
| 05/05/2005 | US20050095288 Compressed core comprising guaifenesin; pseudoephedrine or phenylephrine or salt; controlled release coating |
| 05/05/2005 | US20050095287 Fosinopril composition |
| 05/05/2005 | US20050095286 Adatanserin and/or abaperidone or their salts or derivatives; high or medium viscosity hydroxypropyl methylcellulose and hydroxyethyl cellulose; anxiolytic or antidepressant agents; psychological disorders, schizophrenia; time-release agents |
| 05/05/2005 | US20050095285 Pharmaceutical composition and a process for its preparation |
| 05/05/2005 | US20050095283 Administering antitumor and/or anticarcinogenic agent such as a paclitaxel or taxane derivative formulated in a liposome; Kaposi's sarcoma |
| 05/05/2005 | US20050095281 Vesicle of lipid or phospholipid; and monoglyceride, fatty acid, and/or lysophospholipid active agent; preventing infection from vesicular stomatitis, visna, herpes, myxo-, lymphadenopathy associated, and/or human T-cell leukemia virus; and gonorrhea, chlamdia; time-release agents |
| 05/05/2005 | US20050095279 Transdermal analgesic systems having reduced abuse potential |
| 05/05/2005 | US20050095278 Topical drug delivery using transdermal patch; ointments, creams; oral administration |
| 05/05/2005 | US20050095277 Neuropathy cream |
| 05/05/2005 | US20050095262 Multivitamin syrup for children or young adults |
| 05/05/2005 | US20050095254 DNA immunization against Chlamydia infection |
| 05/05/2005 | US20050095250 treating breast concer by administering a monoclonal antibody with an oligo- beta -(1,3)-glucan and a carrier |
| 05/05/2005 | US20050095248 Use of inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence |